Trends in Pharmacological Sciences
Antidepressant action: to the nucleus and beyond
Section snippets
What is the mechanism of action of antidepressant drugs?
Depression is a clinically and biologically heterogeneous disease. It is one of the most prevalent and costly psychiatric disorders worldwide, with 10–30% of women and 7–15% of men likely to suffer from depression in their life-time [1]. Despite the prevalence and societal cost of depression of an estimated US$50 billion [2], currently used antidepressants do not improve symptoms in all patients. This is, at least in part, the consequence of our limited understanding of the mechanisms of
Antidepressant drugs: beyond neurotransmitters to activation of second messenger pathways and transcriptional regulators
The monoamine hypothesis of depression postulates that a functional deficiency of 5-hydroxytryptamine [5-HT (serotonin)] or noradrenaline in the brain is key to the pathology and/or behavioral manifestations associated with depression 5, 6. In support of this theory, the majority of antidepressant drugs used clinically produce acute increases in the levels of 5-HT and noradrenaline. This in turn causes the activation of seven-transmembrane domain receptors that are coupled to heterotrimeric G
Genetic models of CREB activity
Because antidepressant drugs can activate CREB, recent studies have examined whether manipulation of CREB activity and/or levels of CREB can recapitulate some effects of antidepressants. To date, the function of CREB has been investigated using animal models or viral-vector-mediated gene overexpression (Table 1). Given that the majority of studies have reported increased CREB and/or CREB phosphorylation after chronic antidepressant treatment, the hypothesis of many of these studies was that
Brain-derived nerve growth factor
Plasticity in the nervous system is subserved by a variety of neurotrophins and growth factors. One well-characterized neurotrophic factor involved in activity-dependent neuronal plasticity, survival and differentiation of peripheral and central neurons is brain-derived nerve growth factor (BDNF) 29, 30, 31. Several studies suggest that BDNF is a target of antidepressant action. Robust increases in the levels of BDNF mRNA in cortical and hippocampal regions have been reported following chronic
Genetic models of BDNF action
Mice that lack BDNF display severe neuronal deficits and early postnatal death [31]. However, studies examining mice that lack only one allele of the gene encoding BDNF (BDNF+/−) have identified alterations in learning [46] and synaptic plasticity 47, 48. Some lines of BDNF+/− mice display a reduction in BDNF protein levels but without any accompanying changes in baseline behavior in models such as the FST [49]. Other lines of BDNF+/− mice display altered synaptic responses, but a specific
Insulin like growth factor
Recent studies in rats have identified another neurotrophic factor, insulin-like growth factor (IGF-1), in antidepressant action and neurogenesis. Both systemic and central administration of IGF-1 increase cell proliferation in the adult hippocampus, and IGF-1 has been shown to selectively increase maturation of neurons 53, 54. Central administration of IGF-1 produces antidepressant-like effects in the forced swim tests in rats, which indicates that IGF-1 and IGF-1-induced signal transduction
Antidepressant-induced neurogenesis
Reduced hippocampal cell volume has been observed in depressed humans in both magnetic resonance imaging (MRI) and post-mortem studies, compared with normal individuals 59, 60. Furthermore, antidepressant treatment has been shown to reverse or prevent this decrease in hippocampal volume [61]. Multiple classes of antidepressant drugs increase both cell proliferation and neurogenesis in the dentate gyrus of the adult hippocampus (Table 2), and this requires a chronic, and not an acute,
Conclusions and future directions
Although the field of antidepressant pharmacology has progressed rapidly during the past 10 years, there are many unanswered questions about the function and mechanism by which antidepressants exert their therapeutic effects. Recent research has moved beyond neurotransmitters to understanding the role of second messengers and their targets such as phosphorylated CREB and BDNF. Advanced genetic techniques have enabled the development of various rodent models, which permit evaluation of
References (78)
Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats
Eur. J. Pharmacol.
(2004)Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme
Neuropsychopharmacology
(2002)What turns CREB on?
Cell. Signal.
(2004)Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect
Biol. Psychiatry
(2001)Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety
Biol. Psychiatry
(2004)Postsynaptic target specificity of neurotrophin-induced presynaptic potentiation
Neuron
(2000)Bi-phasic change in BDNF gene expression following antidepressant drug treatment
Neuropharmacology
(2003)Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain
Neuropharmacology
(2003)Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain
Neuropharmacology
(1999)Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain
Biol. Psychiatry
(2003)
Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism
Neuron
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF)
Pharmacol. Biochem. Behav.
Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression
Biol. Psychiatry
Increased synaptic inhibition in dentate gyrus of mice with reduced levels of endogenous brain-derived neurotrophic factor
Neuroscience
Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than “depressive”
Biol. Psychiatry
IGF-I has a direct proliferative effect in adult hippocampal progenitor cells
Mol. Cell. Neurosci.
Central administration of IGF-1 and BDNF leads to long-lasting antidepressant-like effects
Brain Res.
A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin
Ageing Res. Rev.
Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder
Biol. Psychiatry
Selective brain responses to acute and chronic low-dose X-ray irradiation in males and females
Biochem. Biophys. Res. Commun.
Insulin-like growth factor-I and neurogenesis in the adult mammalian brain
Brain Res. Dev. Brain Res.
Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness
Biol. Psychiatry
5-HT1A receptor antagonist administration decreases cell proliferation in the dentate gyrus
Brain Res.
Understanding Antidepressants
Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder
Curr. Med. Res. Opin.
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
J. Neurosci.
Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine
Proc. Natl. Acad. Sci. U. S. A.
The catecholamine hypothesis of affective disorder: a review of supporting evidence
Am. J. Psychiatry
Monoamine dysfunction and the pathophysiology and treatment of depression
J. Clin. Psychiatry
Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs
J. Neurochem.
Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment
Science
Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex
J. Neurochem.
Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
Proc. Natl. Acad. Sci. U. S. A.
Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms
J. Neurosci.
Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs
J. Neurochem.
Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades
Neuropsychopharmacology
Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB
Nature
CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases
Science
Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity
Genes Dev.
Cited by (174)
An insight into crosstalk among multiple signalling pathways contributing to the pathophysiology of PTSD and depressive disorders
2024, Progress in Neuro-Psychopharmacology and Biological PsychiatryNew agents and perspectives in the pharmacological treatment of major depressive disorder
2021, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Evidence points to the involvement of BDNF in the pathophysiology of different mental illnesses, including MDD (Autry and Monteggia, 2012). Moreover, Evidence from animal and clinical studies points to BDNF-associated neurotrophic effects as a possible common downstream process associated with several currently available pharmacological treatments for depression, such as antidepressants, ketamine, scopolamine, and hallucinogens (Björkholm and Monteggia, 2016; Castrén and Kojima, 2017; Malberg and Blendy, 2005). It has been proposed that these neurotrophic effects could be, at least in part, accountable for the long-term improvements in depressive symptoms associated with some of these agents plasticity (Björkholm and Monteggia, 2016; Malberg and Blendy, 2005).
The role of brain-derived neurotrophic factor in neural circuit development and function
2020, Synapse Development and Maturation: Comprehensive Developmental NeuroscienceInflammation and depression: A causal or coincidental link to the pathophysiology?
2018, Acta Neuropsychiatrica